Introduction {#sec1}
============

Nearly half of the world population is at risk of malaria. In 2017, around 435 000 deaths, mostly located in sub-Saharan African regions, were attributed to this disease.^[@ref1]^ The fight against malaria therefore requires the efficient production of antimalarial drugs at a very low cost. Among these, artemisinin is considered to be one of the most potent drugs on the market, and this natural product is mainly obtained by extraction from *Artemisia annua*. However, the world market price is highly volatile, ranging from US \$250 to \$1100 per kilogram.^[@ref2]^ To complement the natural production and narrow the market price fluctuation, a semisynthetic process based on isoprenoid fermentation has been developed.^[@ref3]^ This manufacturing route uses bioengineered microorganisms to produce advanced biosynthetic intermediates such as amorphadiene,^[@ref4]^ artemisinic acid,^[@ref3]^ and more recently dihydroartemisinic aldehyde (**DHAAl**)^[@ref5]^ ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}). The last of these is a key product because it can be obtained directly by fermentation or by means of cost-competitive synthetic chemistry.^[@ref6]^ However, one of the main drawbacks of these strategies is the control of the (11*R*)-configuration of **DHAAl,** which is relatively unstable and this compound is usually obtained as a mixture of two diastereomers ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}).^[@ref5]^

![Semisynthetic Approach toward the Synthesis of Dihydroartemisinic Aldehyde (**DHAAl**)](op9b00481_0001){#sch1}

Optical resolution of racemates via the formation of diastereomers using enantiopure auxiliaries and their separation by crystallization is the preferred large-scale purification method to access highly diastereo- and enantioenriched compounds in pharmaceutical companies.^[@ref7]^ One practical way to realize a diastereo- and enantioenrichment is to use a crystallization-induced diastereomer transformation (CIDT), in which an epimerizable compound is converted into a crystalline diastereomer by condensation with a chiral auxiliary.^[@ref8]^ A particularly useful method to realize CIDT relies on the use of the so-called "Betti base", which was first reported in 1900.^[@ref9]^ In 2003, Košmrlj and Weigel demonstrated that racemic 2-ethylhexanal can be transformed to (*R*)-2-ethylhexanal by CIDT using *trans*-(1*R*,2*R*)-1-amino-6-nitroindan-2-ol.^[@ref10]^ Additional examples have recently been reported in the literature,^[@ref10]−[@ref13]^ and Fülöp et al. showed that treatment of a racemic α-substituted aldehyde with the Betti base leads to the formation of a naphthoxazine ring in which the 1- and 3-substituents are in a trans relationship^[@ref14]^ and that the (*S*)-Betti base induces the formation of the (1′*R*,3′*S*)-naphtoxazine. The epimerization of the stereocenter α to the aldehyde presumably occurs through an imine/enamine equilibrium ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}).

![Formation of One Naphthoxazine Diastereomer by Imine and Enamine Equilibrium](op9b00481_0002){#sch2}

Results and Discussion {#sec2}
======================

In this study, gram-scale quantities of a mixture of (11*R*)- and (11*S*)-**DHAAl** with a diastereomeric ratio (dr) of 65:35 were prepared using a non-stereoselective reduction of artemisinic acid followed by oxidation.^[@ref15]^ In order to improve this ratio, a mixture of (11*R*)- and (11*S*)-**DHAAl** was treated with the (*S*)-Betti base, which was identified as the correct enantiomer to access the desired diastereoenriched (11*R*)-**DHAAl**. Treatment of a 65:35 mixture of **DHAAl** diastereomers with (*S*)-1-(α-aminobenzyl)-2-naphthol \[(*S*)-**2**\] in methanol for 4 h at room temperature (rt) led to the formation of a mixture of naphtho\[1,2-*e*\]\[1,3\]oxazines (1′*R*,3′*S*,11*R*)-**3** and (1′*R*,3′*S*,11*S*)-**3** in a ratio of 72:28.^[@ref16]^ When the reaction was performed on a 0.545 mmol scale, the yield of (1′*R*,3′*S*,11*R*)-**3**/(1′*R*,3′*S*,11*S*)-**3** was 63%, and when the reaction was performed on a larger scale (3.694 mmol), the yield of (1′*R*,3′*S*,11*R*)-**3**/(1′*R*,3′*S*,11*S*)-**3** was increased to 83%. The structures of these isomers were established by ^1^H and ^13^C NMR analysis, while nuclear Overhauser effect (NOE) experiments confirmed that for each isomer, the hydrogen atoms of the 1,3-oxazine ring at C1′ and C3′ are in a trans relationship. The independent preparation of (1′*S*,3′*R*,11*R*)-**3** by reaction of (11*R*)-**DHAAl** with (*S*)-**2** confirmed that the major isomer of the 72:28 mixture is the desired (11*R*)-isomer ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}).

![Synthesis of a 72:28 Mixture of Naphthoxazines **3** and Its Diastereoenrichment\
A mixture of naphthoxazines **3** (11*R*/11*S* = 72:28) (30 mg, 0.133 mmol, 1 equiv) was suspended in CH~3~CN (0.4 mL). AcOH (2 μL from a 10% solution in MeCN, 2.5 mol %) was added, and the suspension was stirred at 65 °C for the indicated times. The white suspension was solubilized in CHCl~3~ (1 mL), and the solution was concentrated under reduced pressure. The diastereomeric excess (de) of **3** was measured by ^1^H NMR spectroscopy of the crude mixture by integration of the aminal protons.](op9b00481_0003){#sch3}

When the 72:28 mixture of (1′*R*,3′*S*,11*R*)-**3** and (1′*R*,3′*S*,11*S*)-**3** was heated in refluxing methanol for an 4 h, no change in the ratio was observed. However, when the same mixture was treated with acetic acid (2.5 mol %) for 3 h in methanol and heated at 65 °C, the (1′*R*,3′*S*,11*S*)-**3** diastereomer was obtained by filtration with a dr of 99:1 in 63% yield. In order to improve the yield of (11*R*)-**DHAAl**, a screening of solvents, temperatures, and times was performed, and the best conditions were to carry out the reaction at 65 °C in acetonitrile for 92 h in the presence of AcOH (2.5 mol %). Under these conditions, (1′*R*,3′*S*,11*R*)-**3** was isolated in 85% yield with a dr of 95:5 in favor of the (11*R*)-isomer. Careful monitoring of the crude reaction mixture over time by ^1^H NMR spectroscopy showed that the diastereomeric excess (de) increased with time in favor of the (11*R*)-isomer ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}).

The crucial step was the hydrolysis of dihydronaphthoxazine **3** to isolate pure **DHAAl** and the recovery of the Betti base. Accordingly, treatment of (1′*S*,3′*S*,11*R*)-**3** with Dowex 50WX8-100 (2 g/mmol) in the presence of a 2% TsOH aqueous solution (0.2 mL/mmol) in THF/EtOAc (1:1) at rt for 14 h led to the isolation of the desired (11*R*)-**DHAAl** epimer in quantitative yield with a dr of 95:5 ([Scheme [4](#sch4){ref-type="scheme"}](#sch4){ref-type="scheme"}). A comparison of the \[α\]~D~ of **DHAAl** obtained by CIDT with the \[α\]~D~ of **DHAAl** prepared by reduction of dihydroartemisinic acid (dr \> 99:1) followed by an oxidation step (Py·SO~3~, Et~3~N, DMSO)^[@ref17]^ allowed us to attribute the *R* absolute configuration of the C11 stereogenic center of **DHAAl** obtained by CIDT \[(\[α\]~D~^25^ +13, *c* 0.98, CHCl~3~ from a sample obtained by CIDT with a dr of 95:5) versus (\[α\]~D~^25^ +16, *c* 0.98, CHCl~3~ from a sample obtained by reduction and oxidation of pure dihydroartemisinic acid with an 11*R*/11*S* ratio of 99:1)\]. It is worth mentioning that the Betti base can be easily recovered at the end of the process in quantitative yield^[@ref18]^ and can be recycled in a new CIDT cycle.^[@ref19]^

![Synthesis of Naphthoxazine **3** and Isolation of Diastereoenriched **DHAAl** Using the Betti Base \[(*S*)-**2**\]](op9b00481_0004){#sch4}

Conclusion {#sec3}
==========

We developed a simple proof-of-concept protocol for the epimerization of the stereogenic center α to the aldehyde of **DHAAl** via a CIDT method utilizing the Betti base, which allowed the isolation of (11*R*)-**DHAAl** with a dr of 95:5 in a nonoptimized overall yield of 71% (three steps). The chiral auxiliary can be easily recovered and reused in another CIDT cycle.^[@ref18],[@ref19]^ This process can potentially offer an alternative to the current route to artemisinin involving hydrogenation, which utilizes an expensive optically active organometallic rhodium catalyst, to control the (11*R*) stereogenic center.^[@ref3]^ CIDT could be an efficient route for the preparation of artemisinin on scale and open more economically viable alternatives to low-cost artemisinin manufacturing.

Experimental Section {#sec4}
====================

General Information {#sec4.1}
-------------------

Reagents were purchased from Aldrich as reagent grade and used without further purification. Dowex 50WX8-100 was also purchased from Aldrich. Reactions were performed in oven-dried glassware under an argon atmosphere. The solvent compositions are reported individually in parentheses. Analytical thin-layer chromatography (TLC) was performed on aluminum sheets coated with silica gel 60 F~254~ (Merck, Macherey-Nagel) or with silica gel 60 RP-18 F~254s~ (Merck, Macherey-Nagel). Visualization was achieved using an alkaline aqueous solution of potassium permanganate. Evaporation of solvents in vacuo was performed at 25--35 °C under 9--10 mbar. Reported yields refer to spectroscopically and chromatographically pure compounds that were dried under high vacuum (0.1--0.05 mbar) before analytical characterization. ^1^H and ^13^C NMR spectra were recorded on a Bruker AV 400 spectrometer at 400 MHz (^1^H) or 101 MHz (^13^C). Chemical shifts (δ) are reported in parts per million upfield using the residual deuterated solvent signals as internal references (CDCl~3~: δ~H~ = 7.26 ppm, δ~C~ = 77.16 ppm). For ^1^H NMR spectra, coupling constants (*J*) are given in hertz, and the resonance multiplicity is described as s (singlet), d (doublet), t (triplet), pent (pentuplet), m (multiplet), or br (broad). All spectra were recorded at 298 K. Infrared (IR) spectra were recorded on a Bruker Tensor 27 FT-IR spectrometer and are reported as wavenumbers ν̃ in reciprocal centimeters. High-resolution mass spectrometry (HRMS) and analyses were performed by the Laboratoire de Spectrométrie de Masse at Sorbonne Université, Paris. Melting points were determined using a Büchi melting point apparatus in open capillaries. The enantiomeric ratios were determined by supercritical fluid chromatography (SFC) on a chiral stationary phase using a Minigram Berger SFC-Mettler Toledo apparatus; *i*PrOH was used as the polar eluent. Nomenclature follows the suggestions proposed by the software ChemDraw Professional 16.0.

(1*S*,3*R*)-3-((*R*)-1-((1*R*,4*R*,4a*S*,8a*S*)-4,7-Dimethyl-1,2,3,4,4a,5,6,8a-octahydronaphthalen-1-yl)ethyl)-1-phenyl-2,3-dihydro-1*H*-naphtho\[1,2-*e*\]\[1,3\]oxazine \[(1′*R*,3′S,11*R*)-**3**\] {#sec4.1.1}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Diastereoenriched dihydroartemisinic aldehyde (11*R*/11*S* = 99:1, 67 mg, 0.304 mmol, 1 equiv) was added to a suspension of (*S*)-Betti base (75 mg, 0.301 mmol, 0.99 equiv) in MeOH (1.3 mL), and the suspension was stirred at 23 °C. After 4 h, the white solid was collected by vacuum filtration, washed with ice-cooled MeOH (2 × 0.4 mL), and dried under reduced pressure to afford the corresponding naphthoxazine as a white solid (79 mg, 58%). Mp: 145--146 °C (MeOH). \[α\]~D~^25^ −24 (*c* 0.92, CHCl~3~). IR (ATR): ν̃ = 2907, 1621, 1598, 1514, 1448, 1389, 1233, 967, 918, 809, 743, 699 cm^--1^. ^1^H NMR (400 MHz, CDCl~3~): δ 7.78 (m, 1H), 7.74 (d, *J* = 9.0 Hz, 1H), 7.43 (m, 1H), 7.34--7.20 (m, 7H), 7.12 (d, *J* = 8.9 Hz, 1H), 5.58 (s, 1H), 5.22 (br s, 1H), 4.82 (d, *J* = 3.0 Hz, 1H), 2.50 (m, NH, 1H), 2.46 (br s, 1H), 2.03 (m, 1H), 1.97--1.73 (m, 3H), 1.61 (br s, 3H), 1.54--1.16 (m, 5H), 1.02 (d, *J* = 6.9 Hz, 3H), 0.83 (d, *J* = 6.2 Hz, 3H), 0.76--0.64 (m, 3H). ^13^C NMR (101 MHz, CDCl~3~): δ 153.5, 142.9, 135.4, 132.1, 129.4 (2C), 129.2, 128.60, 128.59, 128.0 (2C), 127.2, 126.7, 123.2, 123.0, 120.7, 119.5, 115.0, 83.7, 53.7, 42.8, 42.1, 37.4, 37.2, 35.4, 27.8, 26.8, 26.0, 25.5, 24.0, 19.9, 9.8. HR-ESI-MS: *m*/*z* calcd for C~32~H~37~NOH^+^, 452.2948; found, 452.2939 \[M + H\]^+^.

(1*S*,3*R*)-3-((*R*:*S* = 72:28)-1-((1*R*,4*R*,4a*S*,8a*S*)-4,7-Dimethyl-1,2,3,4,4a,5,6,8a-octahydronaphthalen-1-yl)ethyl)-1-phenyl-2,3-dihydro-1*H*-naphtho\[1,2-*e*\]\[1,3\]oxazine \[72:28 (1′*R*,3′*S*,11*R*)-**3**/(1′*R*,3′*S*,11*S*)-3\] {#sec4.1.2}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Dihydroartemisinic aldehyde (11*R*/11*S* = 65:35, 814 mg, 3.694 mmol, 1 equiv) was added to a suspension of (*S*)-Betti base (875 mg, 3.509 mmol, 0.95 equiv) in MeOH (16 mL), and the suspension was stirred at 23 °C for 4 h. The white solid was collected by vacuum filtration, washed with ice-cooled MeOH (2 × 2 mL), and dried under reduced pressure to afford the corresponding naphthoxazines in an 11*R*/11*S* ratio of 72:28 as a white solid (1.317 g, 83%). ^1^H NMR (400 MHz, CDCl~3~): δ 7.78 (m, 1H), \[7.74 (d, *J* = 8.8 Hz, major) and 7.69 (m, minor), 1H\], 7.34--7.18 (m, 7H), 7.12 (d, *J* = 8.9 Hz, 1H), 5.58 (s, 1H), \[5.22 (br s, 0.72H) and 4.91 (br s, 0.28H)\], \[4.82 (d, *J* = 3.0 Hz, 0.72H) and 4.79 (m, 0.28H)\], 2.50 (m, NH, 1H), 2.46 (br s, 1H), 2.04 (m, 1H), 1.97--1.73 (m, 3H), \[1.61 (br s, major) and 1.45 (br s, minor), 3H\], 1.56--1.16 (m, 5H), 1.02 (d, *J* = 6.9 Hz, 3H), \[0.85 (d, *J* = 6.6 Hz, minor) and 0.83 (d, *J* = 6.2 Hz, major), 3H\], 0.73--0.64 (m, 3H). ^13^C NMR (101 MHz, CDCl~3~): δ \[153.5 (major), 153.2 (minor)\], \[143.0 (minor), 142.9 (major)\], \[135.3 (major), 134.7 (minor)\], \[132.1 (major), 131.99 (minor)\], \[129.39 (major, 2C), 129.3 (minor, 2C)\], \[129.2 (major), 129.0 (minor)\], \[128.7 (minor), 128.60 (major)\], \[128.59 (major), 128.5 (minor)\], \[128.3 (minor, 2C), 128.0 (major, 2C)\], \[127.2 (major), 127.1 (minor)\], \[126.7 (major), 126.6 (minor)\], \[123.2 (major), 123.1 (minor)\], 123.0, \[120.8 (minor), 120.7 (major)\], \[119.6 (minor), 119.5 (major)\], \[115.0 (major), 114.9 (minor)\], \[83.7 (major), 82.8 (minor)\], \[54.4 (minor), 53.7 (major)\], 42.8, \[42.14 (major), 42.0 (minor)\], \[39.0 (minor), 37.2 (major)\], \[38.4 (minor), 37.4 (major)\], \[35.9 (minor), 35.4 (major)\], \[28.0 (minor), 27.8 (major)\], \[26.8 (major), 26.6 (minor)\], \[26.4 (minor), 26.0 (major)\], \[25.8 (minor), 25.5 (major)\], \[24.00 (major), 23.8 (minor)\], \[20.0 (minor), 19.9 (major)\], \[11.3 (minor), 9.8 (major)\].

(1*S*,3*R*)-3-((*R*)-1-((1*R*,4*R*,4a*S*,8a*S*)-4,7-Dimethyl-1,2,3,4,4a,5,6,8a-octahydronaphthalen-1-yl)ethyl)-1-phenyl-2,3-dihydro-1*H*-naphtho\[1,2-*e*\]\[1,3\]oxazine \[95:5 (1′*R*,3′*S*,11*R*)-**3**/(1′*R*,3′*S*,11*S*)-**3**\] {#sec4.1.3}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A mixture of naphthoxazines (11*R*/11*S* = 72:28, 150 mg, 0.332 mmol, 1 equiv) was suspended in CH~3~CN (2 mL). AcOH (10% in CH~3~CN, 9 μL, 2.5 mol %) was added, and the suspension was stirred at 65 °C for 92 h. The white suspension was solubilized in CHCl~3~ (5 mL), washed with a saturated aqueous solution of NaHCO~3~ (2 mL) and brine (2 mL), dried over Na~2~SO~4~, filtered, and concentrated under reduced pressure to afford a white solid. The solid was suspended in methanol (1 mL), filtered, and washed with ice-cooled methanol (0.5 mL). The residue was dried under reduced pressure to afford the naphthoxazines in an 11*R*/11*S* ratio of 95:5 as a white solid (85%, 127 mg). Mp: 149--153 °C (MeOH). \[α\]~D~^25^ −19 (*c* 0.68, CHCl~3~). ^1^H NMR (400 MHz, CDCl~3~): δ 7.78--7.74 (m, 2H), 7.45--7.19 (m, 8H), 7.12 (d, *J* = 8.9 Hz, 1H), 5.58 (s, 1H), \[5.22 (br s, 0.95H) and 4.91 (br s, 0.05H)\], \[4.82 (d, *J* = 3.0 Hz, 0.95H) and 4.79 (d, *J* = 3.0 Hz, 0.05H)\], 2.50 (m, NH, 1H), 2.46 (br s, 1H), 2.08--1.73 (m, 4H), 1.61 (br s, 3H), 1.56--1.18 (m, 5H), 1.02 (d, *J* = 6.9 Hz, 3H), \[0.85 (d, *J* = 6.6 Hz, minor) and 0.83 (d, *J* = 6.2 Hz, major), 3H\], 0.75--0.64 (m, 3H). ^13^C NMR (101 MHz, CDCl~3~): δ 153.5, 142.9, 135.4, 132.1, 129.4 (2C), 129.2, 128.60, 128.59, 128.0 (2C), 127.2, 126.7, 123.2, 123.0, 120.7, 119.5, 115.0, 83.7, 53.7, 42.8, 42.1, 37.4, 37.2, 35.4, 27.8, 26.8, 26.0, 25.5, 24.0, 19.9, 9.8.

(*R*)-2-((1*R*,4*R*,4a*S*,8a*S*)-4,7-Dimethyl-1,2,3,4,4a,5,6,8a-octahydronaphthalen-1-yl)propanal \[95:5 (11*R*)-**1**/(11*S*)-**1**\] {#sec4.1.4}
--------------------------------------------------------------------------------------------------------------------------------------

The naphthoxazines (11*R*/11*S* = 95:5, 127 mg, 0.281 mmol) were dissolved in a 1:1 THF/EtOAc solution (1.12 mL). The solution was treated with Dowex 50WX8-100 (0.562 g, 2 g/mmol) and a 2% TsOH aqueous solution (0.056 mL, 0.2 mL/mmol). The suspension was stirred at 23 °C. After 14 h, the suspension was filtered under vacuum, and the brown residue was washed with Et~2~O (1.12 mL × 3, 6 mL/g of resin). The organic layer was cooled with a water/ice bath and washed with a saturated aqueous solution of Na~2~CO~3~ (2 × 3 mL). The organic layer was washed with water (2 × 3 mL) and brine (2 × 3 mL), dried over Na~2~SO~4~, filtered, and concentrated under reduced pressure. The crude residue was filtered on silica gel (85:15 hexanes/EtOAc) to afford dihydroartemisinic aldehyde as a colorless oil (62 mg, quantitative yield). *R*~f~ = 0.78 (SiO~2~; 9:1 petroleum ether/EtOAc). \[α\]~D~^25^ +13 (*c* 0.98, CHCl~3~). IR (ATR): ν̃ = 2912, 2868, 1706, 1449, 1377, 1289, 1264, 1165, 1110, 1078, 1032, 990 cm^--1^. ^1^H NMR (400 MHz, CDCl~3~): δ \[9.63 (d, *J* = 4.0 Hz, 0.05H) and 9.57 (d, *J* = 4.0 Hz, 0.95H)\], \[5.27 (br s, 0.05H) and 5.13 (br s, 0.95H)\], 2.48 (br s, 1H), 2.36 (m, 1H), 2.00--1.76 (m, 3H), 1.64 (br s, 3H), 1.62--1.22 (m, 6H), 1.12 (ddd~app~, *J*~AB~ = 3.3, 13.0, 25.0 Hz, 1H), 1.06 (d, *J* = 7.0 Hz, 3H), 0.95 (ddd~app~, *J*~AB~ = 3.2, 12.1, 26.0 Hz, 1H), 0.87 (d, *J* = 6.5 Hz, 3H). ^13^C NMR (101 MHz, CDCl~3~): δ 206.2, 136.2, 119.7, 48.6, 42.0, 41.6, 36.7, 35.4, 27.8, 27.5, 26.7, 25.9, 24.0, 19.8, 11.9. *t*~R~: 2.84 and 3.07 min (93:7) (SFC, OD-H column, 100 bar, 4 mL/min, isocratic gradient 99:1 CO~2~/*i*PrOH). HR-ESI-MS: *m*/*z* calcd for C~15~H~24~OH^+^, 221.1900; found, 221.1899 \[M + H\]^+^.

Synthesis of (*R*)-2-\[(1*R*,4*R*,4a*S*,8a*S*)-4,7-Dimethyl-1,2,3,4,4a,5,6,8a-octahydronaphthalen-1-yl\]propanal (**DHAAl**) from Dihydroartemisinic Alcohol {#sec4.1.5}
------------------------------------------------------------------------------------------------------------------------------------------------------------

Dihydroartemisinic alcohol (dr \> 98:2, 99 mg, 0.450 mmol, 1 equiv), obtained by LiAlH~4~ reduction of dihydroartemisinic acid, was dissolved in CH~2~Cl~2~ (2 mL) and DMSO (0.5 mL). The mixture was cooled to −10 °C with an ice/NaCl bath and slowly treated with Et~3~N (0.25 mL, 1.80 mmol, 4 equiv). Py·SO~3~ (179 mg, 1.124 mmol, 2.5 equiv) was added in three portions over 20 min. The mixture was allowed to warm to 23 °C and stirred for 16 h. GC/MS analysis showed full conversion of dihydroartemisinic alcohol to **DHAAl**. The mixture was treated with citric acid (aq, 10%, 2 mL) and stirred for 10 min. The layers were then separated, and the organic layer was washed with citric acid (aq, 10%, 2 mL), a saturated aqueous solution of NaHCO~3~ (2 mL), and brine (4 mL), dried over Na~2~SO~4~, filtered, and concentrated under reduced pressure. The yellow residue was filtered on silica gel (85:15 hexanes/EtOAc) to afford **DHAAl** as a colorless oil (81 mg, 82%). It is worth mentioning that when the reaction was performed on 300 mg of dihydroartemisinic alcohol, **DHAAl** was obtained in 97% yield. *R*~f~ = 0.78 (SiO~2~; 9:1 petroleum ether/EtOAc). \[α\]~D~^25^ +16 (*c* 0.98, CHCl~3~). ^1^H NMR (400 MHz, CDCl~3~): δ 9.57 (d, *J* = 4.0 Hz, 1H), 5.13 (br s, 1H), 2.48 (br s, 1H), 2.36 (m, 1H), 2.00--1.76 (m, 3H), 1.64 (br s, 3H), 1.66--1.22 (m, 6H), 1.12 (ddd~app~, *J*~AB~*=* 3.2, 12.6, 25.1 Hz, 1H), 1.06 (d, *J* = 7.0 Hz, 3H), 0.95 (ddd~app~, *J*~AB~*=* 3.2, 12.2, 26.1 Hz, 1H), 0.87 (d, *J* = 6.5 Hz, 3H). ^13^C NMR (101 MHz, CDCl~3~): δ 206.2, 136.2, 119.7, 48.6, 42.0, 41.6, 36.7, 35.4, 27.8, 27.5, 26.7, 25.9, 24.0, 19.8, 11.9. *t*~R~: 2.84 min (SFC, OD-H column, 100 bar, 4 mL/min, isocratic gradient 99:1 CO~2~/*i*PrOH).

Recovery of the Betti Base {#sec4.2}
--------------------------

The solid residue, Dowex/Betti base (562 mg), was suspended in THF (1.23 mL), and then MeOH (0.15 mL) was added, followed by the addition of a 28% NH~4~OH aqueous solution (0.31 mL). The mixture was stirred for 45 min at rt. After filtration, the filtrate was washed with THF (3 × 1 mL), and the solvents were evaporated under reduced pressure. The Betti base was recovered in quantitative yield as a white solid (70 mg, 0.281 mmol). Mp: 130--131 °C (lit.^[@ref1]^ 133--134 °C). \[α\]~D~^25^ +93.0 (*c* 0.42, CHCl~3~) \[lit.^[@ref20]^ +94.1 (*c* 1.0, CHCl~3~)\].

The Supporting Information is available free of charge at [https://pubs.acs.org/doi/10.1021/acs.oprd.9b00481](https://pubs.acs.org/doi/10.1021/acs.oprd.9b00481?goto=supporting-info).Stability of **DHAAl** and naphthoxazines under basic and acidic conditions, ^1^H and ^13^C NMR spectra, and SFC chromatograms ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acs.oprd.9b00481/suppl_file/op9b00481_si_001.pdf))
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